Intravenous thrombolysis in stroke patients with hyperdense middle cerebral artery sign

European Journal of Neurology

Volumn 16, Issue 2, 2009, Pages 162-167

  Georgiadis, D ^a   Wirz, F ^a   Von Budingen H C ^a   Valko, P ^a   Hund Georgiadis, M ^b   Nedeltchev, K ^c   Rousson, V ^a   Baumgartner, R W ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b Rehabilitation Clinic Wald   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Cerebral infarction; Cerebral ischemia; Stroke; Thrombolysis

Indexed keywords

ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE CEREBRAL ARTERY; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; STROKE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOLYTIC THERAPY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 58349094817     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2008.02369.x     Document Type: Article

References (23)

1. Bastianello S, Pierallini A, Colonnese C, et al. Hyperdense middle cerebral artery CT sign. Comparison with angiography in the acute phase of ischemic supratentorial infarction. Neuroradiology 1991 33 : 207 211.
2. Leys D, Pruvo JP, Godefroy O, et al. Prevalence and significance of hyperdense middle cerebral artery in acute stroke. Stroke 1992 23 : 317 324.
3. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. New England Journal of Medicine 1995 333 : 1581 1587.
4. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study. JAMA 1995 274 : 1017 1025.
5. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of 29 thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998 352 : 1245 1251.
6. Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999 282 : 2019 2026.
7. Albers GW, Bates VE, Clark WM, et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000 283 : 1145 1150.
8. Manelfe C, Larrue V, von Kummer R, et al. Association of hyperdense middle cerebral artery sign with clinical outcome in patients treated with tissue plasminogen activator. Stroke 1999 30 : 769 772.
9. Qureshi AI, Ezzeddine MA, Nasar A, et al. Is IV tissue plasminogen activator beneficial in patients with hyperdense artery sign? Neurology 2006 66 : 1171 1174.
10. Tomsick T, Brott T, Barsan W, et al. Prognostic value of the hyperdense middle cerebral artery sign and stroke scale score before ultraearly thrombolytic therapy. American Journal of Neuroradiology 1996 17 : 79 85.
11. Agarwal P, Kumar S, Hariharan S, et al. Hyperdense middle cerebral artery sign: can it be used to select intra-arterial versus intravenous thrombolysis in acute ischemic stroke? Cerebrovascular Diseases 2004 17 : 182 190.
12. Trouillas P, Nighoghossian N, Derex L, et al. Thrombolysis with intravenous rtPA in a series of 100 cases of acute carotid territory stroke: determination of etiological, topographic, and radiological outcome factors. Stroke 1998 29 : 2529 2540.
13. Buttner T, Uffmann M, Gunes N, et al. Early CCT signs of supratentorial brain infarction: clinico-radiological correlations. Acta Neurologica Scandinavica 1997 96 : 317 323.
14. Baumgartner RW, Sidler C, Mosso M, et al. Ischemic lacunar stroke in patients with and without other potential mechanism than small artery disease. Stroke 2003 34 : 653 659.
15. Kawachi I, Colditz GA, Stampfer MJ, et al. Smoking cessation and decreased risk of stroke in women. JAMA 1993 269 : 232 236.
16. Bogousslavsky J, Regli F. Prognosis of symptomatic intracranial obstruction of internal carotid artery. European Neurology 1983 22 : 351 358.
17. Jansen O, von Kummer R, Forsting M, Hacke W, Sartor K. Thrombolytic therapy in acute occlusion of the intracranial internal carotid artery bifurcation. American Journal of Neuroradiology 1995 16 : 1977 1986.
18. Mattle HP, Arnold M, Georgiadis D, et al. Comparison of intraarterial and intravenous thrombolysis for ischemic stroke with hyperdense middle cerebral artery sign. Stroke 2008 39 : 379 383.
19. von Kummer R, Meyding-Lamade U, Forsting M, et al. Sensitivity and prognostic value of early CT in occlusion of the middle cerebral artery trunk. American Journal of Neuroradiology 1994 15 : 9 15.
20. Demchuk AM, Hill MD, Barber PA, et al. Importance of early ischemic computed tomography changes using ASPECTS in NINDS rtPA Stroke Study. Stroke 2005 36 : 2110 2115.
21. Dzialowski I, Hill MD, Coutts SB, et al. Extent of early ischemic changes on computed tomography (CT) before thrombolysis: prognostic value of the Alberta Stroke Program Early CT Score in ECASS II. Stroke 2006 37 : 973 978.
22. Tanne D, Kasner SE, Demchuk AM, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation 2002 105 : 1679 1685.
23. Derex L, Hermier M, Adeleine P, et al. Clinical and imaging predictors of intracerebral haemorrhage in stroke patients treated with intravenous tissue plasminogen activator. Journal of Neurology, Neurosurgery and Psychiatry 2005 76 : 70 75.